Clidinium

證據等級: L5

預測適應症: 10 個

Clidinium: From Gastrointestinal Anticholinergic to Peptic Ulcer Disease

One-Sentence Summary

Clidinium is a quaternary ammonium muscarinic receptor antagonist, classically used in combination with chlordiazepoxide (Librax) for gastrointestinal spasm and functional bowel disorders. Although the TxGNN model's highest-ranked prediction—cauda equina syndrome—is identified as a spurious graph artefact, the model also predicts efficacy for Peptic Ulcer Disease (Rank #4), supported by 7 publications including one controlled clinical trial and one clinical evaluation, making this the most actionable repurposing candidate. Several other high-ranked predictions (myasthenia gravis variants, Ranks 5–7) carry a mechanistic contradiction warning and should not be pursued.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore; classically used as a component of Librax (clidinium + chlordiazepoxide) for GI spasm and irritable bowel syndrome
Predicted New Indication (Most Actionable)	Peptic Ulcer Disease
TxGNN Prediction Score	99.83% (Rank #4 overall; Rank #1 cauda equina syndrome flagged as spurious)
Evidence Level	L3 — Observational studies and controlled clinical evaluations
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank is currently unavailable as a data gap. However, Clidinium is a well-characterised quaternary ammonium compound that acts as an M1/M3 muscarinic receptor antagonist at enteric nerve terminals and gastric parietal cells. By blocking vagally mediated cholinergic input, it reduces basal and stimulated gastric acid secretion and relieves smooth muscle spasm throughout the gastrointestinal tract.

This mechanism directly underpins the plausibility of the peptic ulcer disease prediction. Anticholinergic agents were a cornerstone of peptic ulcer management in the pre-PPI era precisely because of their acid-suppressing and antispasmodic properties. Clidinium in the Librax combination was specifically developed for this indication, and multiple clinical evaluations from the 1960s–1980s documented its use in duodenal and gastroduodenal ulcer. A more recent controlled trial (2016) evaluated clidinium-C as an adjunct to PPI-based triple therapy for Helicobacter pylori eradication, suggesting a contemporary clinical niche may still exist.

By contrast, the model's highest-scoring prediction (cauda equina syndrome, 99.93%) is attributable to a spurious knowledge graph path via a "neurogenic bladder" intermediate node—cauda equina syndrome is a neurosurgical emergency requiring urgent spinal decompression, for which anticholinergic therapy has no mechanistic basis. Similarly, myasthenia gravis predictions (Ranks 5–7) represent direct mechanistic contradictions: standard MG treatment requires enhancing acetylcholine signalling, while Clidinium blocks it.

All Predicted Indications at a Glance

Rank	Indication	TxGNN Score	Evidence Level	Recommendation	Assessment
1	Cauda equina syndrome	99.93%	L5	Hold	Spurious graph path — surgical emergency; anticholinergics irrelevant
2	Neurogenic bladder	99.91%	L4	Research Question	Class-effect plausible; anticholinergics are standard for overactive bladder
3	Gastroduodenitis	99.89%	L4	Research Question	Mechanistically moderate; 2 old case series, no trials
4	Peptic ulcer disease	99.83%	L3	Proceed with Guardrails	Best evidence; controlled evaluations + adjunct trial
5	Myasthenia gravis with thymus hyperplasia	99.71%	L5	Hold	⚠️ Mechanistic contradiction — opposes ACh signalling
6	Limb-girdle autoimmune myasthenia	99.68%	L5	Hold	⚠️ Mechanistic contradiction — potentially harmful
7	Neonatal myasthenia gravis	99.66%	L5	Hold	⚠️ Mechanistic contradiction + high-risk neonatal population
8	Autoimmune disease of PNS	99.63%	L5	Hold	No mechanistic basis; non-specific graph connection
9	Disease of receptor activity	99.61%	L5	Hold	Ontological super-class artefact; structural false positive
10	Large intestine disease	99.16%	L4	Research Question	Plausible for IBS-D; 1 physiological study in NEJM

Clinical Trial Evidence

Currently no related clinical trials are registered for Clidinium in any of the 10 predicted indications (ClinicalTrials.gov and ICTRP searches both returned zero results).

Literature Evidence

Peptic Ulcer Disease (Rank #4 — Primary Focus)

PMID	Year	Type	Journal	Key Findings
27386057	2016	Controlled Clinical Trial	Caspian J Intern Med	Evaluated addition of clidinium-C to 14-day PPI-based triple therapy for H. pylori eradication; assessed whether adjunct anticholinergic improved eradication rate and reduced antibiotic side effects
4892352	1969	Clinical Evaluation (controlled)	Br J Clin Pract	Clinical evaluation of clidinium and Librax in the management of duodenal ulcer; controlled design comparing outcomes
6896942	1982	Clinical Observation	Wiadomosci Lekarskie	Investigated prevention of duodenal ulcer recurrence after cimetidine treatment, with anticholinergic support
14497768	1962	Clinical Trial (early phase)	Minerva Medica	Clinical trials of Librax (clidinium + chlordiazepoxide) across multiple digestive tract diseases including peptic ulcer
14477958	1962	Clinical Case Series	Hospital (Rio de Janeiro)	Treatment of gastroduodenal peptic ulcer with clidinium bromide and chlordiazepoxide combination; preliminary case series
14142206	1964	Clinical Case Series	Rev Clin Espanola	Results with chlordiazepoxide + clidinium bromide (anxiolytic + anticholinergic combination) in gastroduodenal ulcer
28539	1978	Animal Study	Pharmacology	Benzodiazepine–anticholinergic combinations (including clidinium) showed additive/supra-additive protection against stress-induced gastric mucosal erosion in mice

Large Intestine Disease (Rank #10)

PMID	Year	Type	Journal	Key Findings
345122	1978	Clinical Observation (physiological)	N Engl J Med	Studied colonic myoelectrical activity in IBS patients; a single oral dose of clidinium bromide was assessed for its effect on postprandial colonic spike and motor activity

Singapore Market Information

Clidinium (DrugBank: DB00771) has no registered products in Singapore. No license authorisation data is available for this drug.

Safety Considerations

Formal package insert warnings and contraindications are not available as a data gap, and no drug–drug interaction data was retrieved. Please refer to the package insert for complete safety information.

Critical mechanistic safety flags identified from prediction analysis:

Myasthenia gravis (all forms — Ranks 5, 6, 7): Anticholinergic agents are fundamentally contraindicated in myasthenia gravis. Standard MG treatment relies on acetylcholinesterase inhibitors (e.g., pyridostigmine) to amplify ACh signalling at the neuromuscular junction; Clidinium's muscarinic blockade opposes this mechanism and could precipitate myasthenic crisis. The risk is compounded in neonates (Rank 7), who have immature hepatic metabolism and reduced clearance capacity.
Cauda equina syndrome (Rank 1): This is a neurosurgical emergency where bladder dysfunction is a key monitoring indicator. Anticholinergic suppression of bladder sensation could mask symptom progression and delay life-saving surgical intervention.

Conclusion and Next Steps

Decision: Proceed with Guardrails (Peptic Ulcer Disease only — all other indications require Hold or further research)

Rationale: Clidinium has a mechanistically sound and historically documented role in peptic ulcer disease, with controlled clinical evaluations spanning the 1960s through a 2016 adjunct H. pylori eradication trial. However, the evidence base predates modern RCT standards, and the drug is not currently marketed in Singapore, requiring a full regulatory pathway assessment before any clinical application.

Hard stops — do not proceed:

Ranks 5, 6, 7 (all myasthenia gravis variants): Direct mechanistic contradiction; pursuing these predictions would be clinically harmful
Rank 1 (cauda equina syndrome): Spurious graph artefact; surgical emergency outside the scope of pharmacotherapy
Rank 9 (disease of receptor activity): Ontological classification node, not a real clinical entity

To proceed with peptic ulcer disease investigation, the following is needed:

Full MOA data from DrugBank (data gap — required for mechanistic confirmation)
Package insert warnings and contraindications (data gap — required for safety screening)
Drug–drug interaction assessment, particularly with CNS depressants and other anticholinergics (data gap)
Modern systematic review or meta-analysis of anticholinergics as adjuncts to H. pylori eradication therapy
Clarification of whether the target formulation is standalone Clidinium or the Librax combination (clidinium + chlordiazepoxide), as efficacy evidence is largely combination-based
Singapore regulatory pathway assessment (no existing market authorisation)
Phase 2 proof-of-concept trial design if historical evidence review is supportive
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.